CRV-101 is a next-generation shingles vaccine candidate designed to maximize the CMI protection by combining the gE protein antigen with our proprietary adjuvant
An effective VZV vaccine requires potent induction of VZV-specific cell-mediated immunity(CMI) since reduced CMI to VZV has been associated with increased risks of developing shingles
CMI: powerful means of immune protection against virus infection is mediated by T cells in the body.
This is called Cell-Mediated Immune (CMI) responses through triggering antigen-specific T cells that eliminate infected cells in the system.
CRV 101 is indicated to prevent shingles in adults age 50 and older
November 5, 2018: Curevo announced that the U.S. Food and Drug Administration (FDA) has advanced the company's Investigational New Drug (IND) application for CRV-101.
Clinical Trial NCT03820414: Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects